Abstracts tagged "Scleredema"

Abstract Number: 1056 • 2019 ACR/ARP Annual Meeting
Profibrotic Macrophage Activation in Systemic Sclerosis Is Dependent on the Mechanosensing MRTF-A Pathway
Tricia Lim¹, Kristina Krogmannova ¹, Shiwen Xu ¹, Bahja Ahmed Abdi ², David Abraham ¹, Christopher Denton ³ and Richard Stratton ¹, ¹University College London, London, United Kingdom, ²University College London, London, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom
Background/Purpose: An M2-like alternative activation state of macrophages has been linked to the pathogenesis of several fibrotic disorders, including systemic sclerosis (SSc). MRTF-A is an…
Abstract Number: 1058 • 2019 ACR/ARP Annual Meeting
Inhibition of Histone Readers Bromodomain and Extraterminal Domain Proteins Alleviates Scleroderma Fibrosis
Sirapa Vichaikul ¹, Phillip Campbell ², M. Asif Amin ³, Jeffrey H. Ruth ³, Dallas Rohraff ¹, David Fox ⁴, Dinesh Khanna ⁵, Amr Sawalha ⁶ and Pei-Suen Tsou³, ¹University of Michigan, Ann Arbor, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor, MI, ⁴Division of Rheumatology, Department of Internal Medicine, Autoimmunity Center of Excellence,University of Michigan, Ann Arbor, MI, ⁵Scleroderma Program, Division of Rheumatology, Department of Internal Medicine, Autoimmunity Center of Excellence, University of Michigan, Ann Arbor, ⁶University of Pittsburgh & University of Michigan, Pittsburgh, PA
Background/Purpose: Epigenetic regulation, including histone acetylation, plays an important role in scleroderma (SSc) fibrosis. The binding of the bromodomain and extra-terminal domain proteins (BRDs) to…
Abstract Number: 1074 • 2019 ACR/ARP Annual Meeting
Epigenetic Regulation-Mediated Reduction in the Expression of Prostacyclin Receptor and Prostacyclin Synthase in Scleroderma Skin, Vascular Smooth Muscle Cells, and Microvascular Endothelial Cells
Yongqing Wang ¹, nezam Altorok ² and Bashar Kahaleh², ¹University of Toeldo, TOLEDO, OH, ²University of Toledo, Toledo, OH
Background/Purpose: Progressive functional and structural vascular disorder is one of the hallmark features of Systemic Sclerosis (Scleroderma, SSc). Vascular dysfunction lead to dysregulated vascular tone…
Abstract Number: 1635 • 2019 ACR/ARP Annual Meeting
Correlation Between Raynaud’s Condition Score, Nailfold Videocapillaroscopy and Laser Speckle Contrast Analysis in Secondary Raynaud’s Phenomenon Due to Systemic Sclerosis
Barbara Ruaro¹, Elisa Alessandri ², Massimo Ghio ³, Carmen Pizzorni ⁴, Sabrina Paolino ⁴, Andrea Casabella ⁵, Antonio De Tanti ⁶, Alberto Sulli ⁷ and Maurizio Cutolo ⁸, ¹1 Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 2 Cardinal Ferrari Centre, S. Stefano Rheabilitation, Fontanellato (Parma), Italy, Genoa, Italy, ²1. Research Laboratory and Academic Division of the Clinical Rheumatology Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ³Research Laboratory and Academic Division of the Clinical Rheumatology Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁵1 Research Laboratory and Academic Division of the Clinical Rheumatology Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁶2 Cardinal Ferrari Centre, S. Stefano Rheabilitation, Fontanellato (Parma), Italy, Fontanellato, Italy, ⁷Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ⁸Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy
Background/Purpose: To evaluate any correlation between the Raynaud's Condition Score (RCS) and the morphological and functional methods available to evaluate microvascular damage in systemic sclerosis (SSc) patients (1-4). Methods: Sixty-six…
Abstract Number: 2745 • 2019 ACR/ARP Annual Meeting
Iguratimod Treated Scleroderma with Interrupted Egr1/TGF-β Loop
Qingran Yan¹, Lichong Shen ¹, Xiaoxiang Chen ¹ and Liangjing Lu ¹, ¹Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of medicine, Shanghai, China (People's Republic)
Background/Purpose: Iguratimod is a novel disease modifying anti-rheumatic drug that has been approved for treating rheumatoid arthritis in East Asia. Transcription factor early growth response…
Abstract Number: 122 • 2018 ACR/ARHP Annual Meeting
Metformin Inhibited the Development of Bleomycin-Induced Murine Scleroderma Via Restoring the Balance between Regulatory and Effector T Cells and Suppressing Spleen Germinal Center Formation
Yanlin Wang¹, Zhaojun Liang², Xiangcong Zhao¹, Chong Gao³ and Jing Luo⁴, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China, ²Division of Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China, Taiyuan, China, ³Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA, ⁴the Second Hospital of Shanxi Medical University, Taiyuan, China
Background/Purpose: Scleroderma is a multisystem connective tissue disease characterized by extensive tissue fibrosis and its three prominent cardinal features are vasculopathy, excessive collagen deposition and immunological abnormalities. Metformin (MET)…
Abstract Number: 901 • 2018 ACR/ARHP Annual Meeting
Changes in Quantitative Scleroderma Lung CT Measures in Patients Treated with Cyclophosphamide or Transplantation
Jonathan Goldin¹, Lynette Keyes-Elstein², Leslie Crofford³, Daniel E. Furst⁴, Ellen Goldmuntz⁵, Maureen D. Mayes⁶, Peter McSweeney⁷, Richard Nash⁷, Hyun J. Grace Kim⁸, Mathew Brown⁹ and Keith Sullivan¹⁰, ¹Department of Radiological Sciences at UCLA, University of California, Los Angeles, David Geffen School of Medicine, Santa Monica, CA, ²Rho, Inc, Chapel Hill, NC, ³Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ⁴University of Washington, Seattle, WA, ⁵NIAID, NIH, Bethesda, MD, ⁶Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁷Colorado Blood Cancer Institute, Denver, CO, ⁸Radiology, UCLA, LA, CA, ⁹Radiology, UCLA, Los Angeles, CA, ¹⁰Duke University Medical Center, Durham, NC
Background/Purpose: Scleroderma related interstitial lung disease (SLD) is a major cause of morbidity and mortality in severe systemic sclerosis (SSc). The Scleroderma: Cyclophosphamide or Transplantation…
Abstract Number: 1423 • 2018 ACR/ARHP Annual Meeting
Autoantibody Testing in Pediatric Localized Scleroderma (LS)
Aidan Porter¹, Emily Mirizio², Marvin J. Fritzler³, Rachael Brown⁴, May Choi³, Kaila Schollaert-Fitch⁵, Christopher Liu⁵ and Kathryn S. Torok⁶, ¹Peds, University of Pittsburgh Med Ctr, Pittsburgh, PA, ²Peds Rheum, University of Pittsburgh Med Ctr, Pittsburgh, PA, ³Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁶Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA
Background/Purpose: Pediatric localized scleroderma (LS) is typically categorized by the depth and extent of skin lesions into main subtypes: linear scleroderma, including linear trunk/limb and…
Abstract Number: 1731 • 2018 ACR/ARHP Annual Meeting
Vertebral Fracture Prevalence and Measurement of the Scanographic Bone Attenuation Coefficient on CT-Scan in 70 Patients with Systemic Scleroderma
Marine FAUNY¹, Elodie BAUER², Eliane ALBUISSON³, Julia Perrier-Cornet¹, Joelle DEIBENER⁴, Francois CHABOT⁵, Damien MANDRY⁶, Olivier HUTTIN⁷, Isabelle Chary-Valckenaere⁸ and Damien Loeuille², ¹Rheumatology, University Hospital of Nancy, VANDOEUVRE LES NANCY, France, ²Rheumatology, University Hospital of Nancy, NANCY, France, ³University Hospital of Nancy, Nancy, France, ⁴Internal Medicine, University Hospital of Nancy, NANCY, France, ⁵Pneumology, University Hospital of Nancy, NANCY, France, ⁶Radiology, University Hospital of Nancy, NANCY, France, ⁷Cardiology, University Hospital of Nancy, NANCY, France, ⁸Rheumatology, CHRU Nancy, Vandoeuvres les Nancy, France
Background/Purpose: Osteoporosis screening is not systematic in sclerodermic patients but some studies demonstrated a similar risk between rheumatoid arthritis and systemic scleroderma [1,2,3]. Thoracic and/or…
Abstract Number: 98 • 2017 ACR/ARHP Annual Meeting
Impact of a Lung Ultrasound Course for Rheumatology Specialist (IMPACT-2)
Christopher Gasho¹, Karina Torralba², David Chooljian³, Cong-Bin Wang⁴ and Vi Dinh⁴, ¹Pulmonary and Critical Care Medicine, Loma Linda Medical Center, 12354 Anderson St, CA, ²Division of Rheumatology, Department of Internal Medicine, Loma Linda University, Loma Linda, CA, ³Loma Linda Veteran Affairs Hospital, Loma Linda, CA, ⁴Loma Linda University Medical Center, Loma Linda, CA
Background/Purpose: Although much emphasis is focused on lung ultrasonography(US) within the critical care field, there is a growing interest in the use of lung…
Abstract Number: 754 • 2017 ACR/ARHP Annual Meeting
Interferon Siganture in Systemic Sclerosis Lung Microvascular Endothelial Cells
Fabian A Mendoza¹, Sonsoles Piera-Velazquez², Peter J. Wermuth³, Sankar Addya⁴, Carol A. Feghali-Bostwick⁵ and Sergio A. Jimenez⁶, ¹Rheumatology Division, Department of Medicine, Thomas Jefferson University, Jefferson Institute of Molecular Medicine and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, ²Jefferson Institute of Molecular Medicine and Scleroderma Center., Thomas Jefferson University, Philadelphia, PA, ³Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, ⁴Kimmel Cancer Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, ⁵Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ⁶Scleroderma Center and Jefferson Institute of Molecular Medicine, Thomas Jefferson Univ, Philadelphia, PA
Background/Purpose: Systemic Sclerosis (SSc) is characterized by severe fibroproliferative vasculopathy, exaggerated deposition of extracellular matrix molecules (ECM) in skin and multiple internal organs, and alterations…
Abstract Number: 765 • 2017 ACR/ARHP Annual Meeting
Proteomic Analysis of Scleroderma Associated Joint Disease
Chan Kim¹, Julio Mantero², Robert A. Lafyatis³ and Robert W. Simms⁴, ¹Rheumatology and Clinical Epidemiology, Boston University School of Medicine, Boston, MA, ²Arthritis Center, Boston University School of Medicine, Boston, MA, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose: The pathophysiology of joint disease in scleroderma, a heterogeneous multisystem disease mostly characterized by fibrosis, is unknown. We performed proteomic analysis of serum in…
Abstract Number: 1258 • 2017 ACR/ARHP Annual Meeting
Divided By a Common Language: Challenges in Physician-Patient Communication Limit Patient Understanding and Support in Systemic Sclerosis with Interstitial Lung Disease (SSc-ILD)
Christopher Denton¹, Bee Laird², Lizette Moros³ and José Luis Luna Flores⁴, ¹Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom, ²Reframe Research, East Sussex, United Kingdom, ³Boehringer-Ingelheim, Ingelheim, Germany, ⁴Boehringer Ingelheim, Ingelheim, Germany
Background/Purpose: Systemic sclerosis is a potentially life-threatening, clinically diverse, and rare condition. The prognosis and course of disease is difficult to predict and treatment is…
Abstract Number: 1724 • 2017 ACR/ARHP Annual Meeting
Metabolic Regulation of Fibrosis in Systemic Sclerosis: The CD38-NAD+ Link
Bo Shi¹, Wenxia Wang¹, Jun Wei², Swati Bhattacharyya¹, Benjamin Korman³, Eduardo Chini⁴ and John Varga⁵, ¹Northwestern University, Chicago, IL, ²Northwestern University, chicago, IL, ³Department of Rheumatology, Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁴Kogod Center on Aging, Mayo Clinic, Rochester, MN, ⁵Rheumatology and Dermatology, Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL
Background/Purpose: The anti-aging deacetylase enzymes SIRT1 and SIRT3 show potent anti-fibrotic activity, and their expression and function are markedly deregulated in patients with systemic sclerosis…
Abstract Number: 820 • 2016 ACR/ARHP Annual Meeting
EZH2 Modulates Angiogenesis and Fibrosis in Scleroderma
Pei-Suen Tsou, Patrick Coit, Dinesh Khanna and Amr H Sawalha, Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Scleroderma (SSc) is a complex disease that involves activation of the immune system, vascular complications, and tissue fibrosis. Although the pathogenesis of this disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].